OctoPlus Opens new GMP Manufacturing Facility
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
OctoPlus N.V. has announced that it has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products according to international GMP (Good Manufacturing Practice) guidelines and the first production has taken place successfully.
The expansion of OctoPlus' headquarters started in November 2006. The new building comprises offices, laboratories and a GMP manufacturing plant that produces final drug product for OctoPlus' clients. Expansion of the manufacturing capacity was necessary to facilitate the growing demand from OctoPlus' clients.
With the expansion, OctoPlus' manufacturing capacity more than doubled and the Company can now produce clinical scale Phase I, II, III and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.
Simon Sturge, CEO of OctoPlus comments: "We are very proud to report that the expansion of the production facility in our headquarters in Leiden has obtained official approval from the Dutch authorities and we have now started producing pharmaceutical products as a fully licensed facility."
The expansion of OctoPlus' headquarters started in November 2006. The new building comprises offices, laboratories and a GMP manufacturing plant that produces final drug product for OctoPlus' clients. Expansion of the manufacturing capacity was necessary to facilitate the growing demand from OctoPlus' clients.
With the expansion, OctoPlus' manufacturing capacity more than doubled and the Company can now produce clinical scale Phase I, II, III and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.
Simon Sturge, CEO of OctoPlus comments: "We are very proud to report that the expansion of the production facility in our headquarters in Leiden has obtained official approval from the Dutch authorities and we have now started producing pharmaceutical products as a fully licensed facility."
